Cairo, Egypt - April 30, 2024 - EVA Pharma, a leading pharmaceutical and scientific research company, has achieved a breakthrough by obtaining marketing authorization for its Ondansetron medication in Canada, a medical product used to treat nausea and vomiting, both in normal and severe cases such as after surgery, chemotherapy, or radiation therapy.

Dr. Nicolas Boge, Developed Markets Commercial Director at EVA Pharma, said that the company's success in registering the drug and other pharmaceutical products in Canada and other developed countries represents the commitment of EVA Pharma's adherence to the highest international quality standards in its manufacturing for trading both in Egypt and more than 40 countries globally.

Dr. Boge added: “We are keen to expand our business and reach global standards by manufacturing products in Egypt and several other countries while maintaining the most rigorous international quality standards. Such quality standards and accreditations from international drug regulatory bodies such as the European Medicines Agency and the Canadian Ministry of Health. allow us to penetrate several global markets easily.”

He also pointed out that EVA Pharma is taking further steps to expand in the Arab, Middle East, and several European markets, as part of its plan to empower the fight for health and well-being as a human right.

EVA Pharma, established in 1997 in Egypt, is a leading pharmaceutical company in the Middle East and North Africa, and is one of the strong and influential entities affiliated with EVA Group, which has a history in the pharmaceutical market for more than 100 years. EVA Pharma produces more than 300 products in 10 different therapeutic areas. The company has a global reach in 40+ countries, including European countries and Canada, and this recent marketing authorization is part of their ongoing journey of globalization.
About EVA Pharma

                                                                                                                     -ENDS-
About EVA Pharma

EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand. EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.

For more information, please visit: www.evapharma.com & https://www.evapharma.com/newsroom or follow us on LinkedIn 

Media Contact:

Ahmed Ellewa | Public Relations Head | ahmed.ellewa@evapharma.com | +20-1000-053-643